
AbbVie (ABBV) Stock Forecast & Price Target
AbbVie (ABBV) Analyst Ratings
Bulls say
AbbVie has reaffirmed its guidance for a high single-digit sales compound annual growth rate (CAGR) from 2024 to 2029, signaling robust growth potential driven primarily by its strong immunology products, Skyrizi and Rinvoq, with anticipated sales exceeding $20 billion and $11 billion, respectively, by 2027. The company's fourth-quarter 2024 results exceeded expectations, with sales reaching $15.1 billion, highlighting the performance of its key immunology offerings. Despite a softened outlook for its Aesthetics franchise, AbbVie's adjusted long-term revenue projections and initial earnings per share guidance for 2025 demonstrate a solid foundation for sustainable growth moving forward.
Bears say
AbbVie faces several significant risks that contribute to a negative outlook on its stock. The company is grappling with disappointing sales performance in its key products, such as Humira and its aesthetic offerings, while experiencing competitive pressures in both its immunology and oncology segments. Furthermore, ongoing macroeconomic challenges, potential regulatory setbacks, and heightened risks in the clinical development pipeline may hinder the company's ability to achieve its long-term growth expectations.
This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.
AbbVie (ABBV) Analyst Forecast & Price Prediction
Start investing in AbbVie (ABBV)
Order type
Buy in
Order amount
Est. shares
0 shares